The prolonged, 1–2 days, circulation of the 2pHLIP-dMSA in the blood leads to the improvement of tumor targeting and delivery of sufficient amounts of STINGa to tumors, which is required to induce strong transient activation of the STING pathway in cancer, stromal and immune cells simultaneously. This evidence concerns the gene STING1 and cancer.